Keyphrases
LysR Family
100%
Cryptosporidium
100%
Mode of Action
50%
Target Engagement
50%
Selection Marker
50%
Anticryptosporidial
50%
Efficacy in Vivo
50%
Cryptosporidiosis
32%
Calf Model
25%
Nitazoxanide
25%
Compound Properties
25%
Potential Treatments
25%
Neglected Infectious Diseases
25%
Gastrointestinal Infection
25%
Infection Model
25%
Lack of Understanding
25%
Immunodeficient Mice
25%
Unmet Medical Need
25%
Leading Causes of Death
25%
Knowledge Gaps
25%
Preclinical Safety Studies
25%
Mouse Infection
25%
Physicochemical Properties
25%
Clinical High Risk
25%
Diarrheal Disease
25%
Mouse Model
25%
Pharmacokinetic Properties
25%
Drug Discovery
14%
Drug Selection
14%
Genetic Approach
14%
Thermal Proteome Profiling
14%
Genetic Tools
14%
Genetic Modification
14%
Binding Site
7%
Chemical Tools
7%
Overexpressing
7%
Children under 5 Years
7%
Effective Treatment
7%
Associated Morbidity
7%
Parental Strain
7%
Parasite Survival
7%
Parasite Biology
7%
Clinical Outcomes
7%
Parvum
7%
New Therapeutics
7%
Unbiased Approach
7%
Reverse Genetics
7%
Low-middle Income Countries
7%
Target Identification
7%
Drug Target
7%
Forward Genetics
7%
Hybrid Progeny
7%
Molecular Targets
7%
Genetic Crosses
7%
High Efficiency
7%
Pharmacology, Toxicology and Pharmaceutical Science
Lysine Transfer RNA Ligase
100%
Cryptosporidium
100%
Infection
50%
Mouse Model
25%
Diseases
25%
Cryptosporidiosis
19%
Drug Discovery
14%
Pharmacokinetics
12%
Gastrointestinal Infection
12%
Nitazoxanide
12%
Target Identification
7%
Binding Site
7%
Molecular Target
7%
Biochemistry, Genetics and Molecular Biology
Transfer RNA
50%
Cryptosporidium
50%
Proteome
14%
Genetic Approach
14%
Life Cycle
14%
Genetics
14%
Forward Genetics
7%
Genetic Cross
7%
Binding Site
7%
DNA Modification
7%
Parasite Survival
7%